Secukinumab (AIN457) is a fully human anti-IL-17A IgG1κ monoclonal antibody (mAb), being studied in clinical trials in psoriasis, RA, Crohn's disease (CD), psoriatic arthritis (PsA), ankylosing spondylitis and MS. Here, IL17A is linked to psoriatic arthritis.